S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

IONS Ionis Pharmaceuticals Inc

41.97

0.00 (0.00%)

Pre Market

Last Updated: 18:00:05

Delayed by 15 minutes

ISIS Pharmaceuticals Stock Rating Lowered by Zacks (ISIS)

http://www.tickerreport.com/banking-finance/495515/isis-pharmaceuticals-stock-rating-lowered-by-zacks-isis/?utm_source=ADVFN&utm_medium=banner&utm_campaign=ADVFN

Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Ionis Pharmaceuticals Charts.

Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Ionis Pharmaceuticals Charts.

News

Ionis Publishes 2023 Corporate Responsibility Report
Thursday 25 April 2024 (2 weeks ago) • PR Newswire (US)

Ionis to hold first quarter 2024 financial results webcast
Tuesday 23 April 2024 (2 weeks ago) • PR Newswire (US)

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Sunday 7 April 2024 (4 weeks ago) • PR Newswire (US)

Ionis to present at upcoming investor conferences
Monday 1 April 2024 (1 month ago) • PR Newswire (US)

Ionis to hold olezarsen Phase 3 data webcast
Thursday 28 March 2024 (1 month ago) • PR Newswire (US)

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Monday 25 March 2024 (1 month ago) • PR Newswire (US)

Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Wednesday 13 March 2024 (2 months ago) • PR Newswire (US)

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Wednesday 6 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

More News Articles

JP Morgan Chase

Woodside Petroleum

Invesco QQQ Trust Series 1

National Australia Bank

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions